Characteristics of Adult Outpatients and Inpatients with COVID-19 …
This report describes survey findings of adult inpatients and outpatients who tested positive for SARS-CoV-2 infection.
Related Articles
Submitter Login Page – IDWeek 2023 Applications – IDWeek 2024 Applications
ID Week has partnered with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to create a Fellows Exchange Program. Through the program, two…
Talk Test Treat for Providers
Health care providers can empower patients to take care of their sexual health
Podcasts Killed the Radio Star
Buddy Creech, MD, MPH, FPIDS, and Febrile creator and infectious diseases physician, Sara Dong, MD, discuss the power of digital education tools on infectious diseases…
From data to care: How AI can transform public health
Researchers used public health datasets to train machine learning models to predict HIV incidence with high accuracy.
Board of Directors Call for Volunteers
The call for officer and director applications for the IDSA Board of Directors is now open. We are seeking volunteers for the office of Vice…
Science Speaks Blog
With regular posts, IDSA’s and HIVMA’s blog reminds readers that infectious diseases don’ t observe national borders, and effective, evidence-based responses protect us all. With…
Syphilis surge: The great imitator strikes again
HIVMA Board member Joseph Cherabie, MD, MSc (@JncherabieMD), provides a front-line perspective on the surge in syphilis cases and shares practical tips for clinicians.
How New Regulation of Laboratory-Developed Antimicrobial Susceptibility Tests Will Affect Infectious Diseases Clinical Practice
Abstract. Antimicrobial resistance (AMR) affects 2.8 million Americans annually. AMR is identified through antimicrobial susceptibility testing (AST), but
Society Awards
Clinical Practice Innovation Award; D.A. Henderson Award for Outstanding Contributions to Public Health; Alexander Fleming Award for Lifetime Achievement; The Watanakunakorn Clinician Award; The Walter…
Clade I Mpox Response
Mati Hlatshwayo Davis, MD, MPH, FIDSA discusses the clade I mpox response with guests Jennifer McQuiston, DVM, and Agam Rao, MD, FIDSA of the CDC.